EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In silico study of lutein as anti-HER-2 receptors in breast cancer treatment

Ni Ketut Nitya Cahyani, Wahyu Nadi Eka Putri, I Kadek Diva Dwivayana, Ni Putu Dinda Mirayanti, Ni Putu Linda Laksmiani

Pharmacy Reports · 2021

DOI: 10.51511/pr.17 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy Reports, 2021. Verfasst von Ni Ketut Nitya Cahyani und 4 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kementerian Riset, Teknologi dan Pendidikan Tinggi.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human Epidermal Receptor-2 (HER-2) overexpression is implicated in breast cancer progression; thus, HER-2 is widely used as the target of anticancer therapy. Lapatinib is a drug widely used to inhibit the HER-2 receptor and tyrosine kinase; however, it develops drug resistance. Lutein is promising to be developed as breast cancer therapy. This study aims to determine the mechanism of inhibition of HER-2 receptor overexpression by lutein in silico. Molecular docking was carried out by optimizing the lutein and lapatinib, preparing of protein target HER-2 (PDB ID 3PP0), validating of molecular docking protocol, and docking of lutein and lapatinib on HER-2. The study resulted in the binding energy of -12.37 kcal/mol, while the binding energy of the native ligand and lapatinib to HER-2 was -10.43 kcal/mol and -12.25 kcal/mol, respectively. The binding energy showed that lutein has potential as breast anticancer suggested from the stronger affinity to HER2.

Förderung

  • Kementerian Riset, Teknologi dan Pendidikan Tinggi

Zitieren

APA

Cahyani, N. K. N., Putri, W. N. E., Dwivayana, I. K. D., Mirayanti, N. P. D., & Laksmiani, N. P. L. (2021). In silico study of lutein as anti-HER-2 receptors in breast cancer treatment. Pharmacy Reports. https://doi.org/10.51511/pr.17

Vancouver

Cahyani NKN, Putri WNE, Dwivayana IKD, Mirayanti NPD, Laksmiani NPL. In silico study of lutein as anti-HER-2 receptors in breast cancer treatment. Pharmacy Reports. 2021. doi:10.51511/pr.17

BibTeX
@article{Cahyani2021,
  author = {Cahyani, Ni Ketut Nitya and Putri, Wahyu Nadi Eka and Dwivayana, I Kadek Diva and Mirayanti, Ni Putu Dinda and Laksmiani, Ni Putu Linda},
  title = {In silico study of lutein as anti-HER-2 receptors in breast cancer treatment},
  journal = {Pharmacy Reports},
  year = {2021},
  doi = {10.51511/pr.17}
}
Kostenlos starten →